Literature DB >> 11435907

Adenosine A2A agonist CGS 21680 decreases the affinity of dopamine D2 receptors for dopamine in human striatum.

Z Díaz-Cabiale1, Y Hurd, D Guidolin, U B Finnman, M Zoli, L F Agnati, J J Vanderhaeghen, K Fuxe, S Ferré.   

Abstract

Adenosine A2A receptors (A2AR) and dopamine D2 receptors (D2R) are highly concentrated in the striatum, where they are co-localized and exert reciprocal antagonistic interactions. It has been suggested that the A2R/D2R interactions might provide a therapeutic approach for basal ganglia disorders, such as Parkinson's disease, and schizophrenia. In the present work evidence is presented for the existence of an A2AR/D2R interaction in human brain by using quantitative autoradi- ography. The areas analyzed were the dorsal caudate nucleus and putamen. Parallel studies were performed in rat striatal sections. The A2AR agonist CGS 21680 was found to significantly increase IC50 values of competitive inhibition curves of the D2R/D3R antagonist [125I]iodosulpiride vs dopamine both in rat striatal and human striatal brain sections.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11435907     DOI: 10.1097/00001756-200107030-00014

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  27 in total

1.  Effects of protein kinase A inhibitor and activator on rewarding effects of SKF-82958 microinjected into nucleus accumbens shell of ad libitum fed and food-restricted rats.

Authors:  Soledad Cabeza de Vaca; Xing-Xiang Peng; Seth Concors; Casey Farin; Elena Lascu; Kenneth D Carr
Journal:  Psychopharmacology (Berl)       Date:  2011-12-07       Impact factor: 4.530

Review 2.  Adenosine-dopamine interactions in the pathophysiology and treatment of CNS disorders.

Authors:  K Fuxe; D Marcellino; D O Borroto-Escuela; M Guescini; V Fernández-Dueñas; S Tanganelli; A Rivera; F Ciruela; L F Agnati
Journal:  CNS Neurosci Ther       Date:  2010-03-16       Impact factor: 5.243

Review 3.  Adenosine A2A and dopamine D2 heteromeric receptor complexes and their function.

Authors:  Kjell Fuxe; Sergi Ferré; Meritxell Canals; Maria Torvinen; Anton Terasmaa; Daniel Marcellino; Steven R Goldberg; William Staines; Kirsten X Jacobsen; Carmen Lluis; Amina S Woods; Luigi F Agnati; Rafael Franco
Journal:  J Mol Neurosci       Date:  2005       Impact factor: 3.444

4.  Low affinity binding of the classical D1 antagonist SCH23390 in rodent brain: potential interaction with A2A and D2-like receptors.

Authors:  Sarah K Leonard; Penelope Ferry-Leeper; Richard B Mailman
Journal:  Brain Res       Date:  2006-09-07       Impact factor: 3.252

Review 5.  Intramembrane receptor-receptor interactions: a novel principle in molecular medicine.

Authors:  K Fuxe; M Canals; M Torvinen; D Marcellino; A Terasmaa; S Genedani; G Leo; D Guidolin; Z Diaz-Cabiale; A Rivera; L Lundstrom; U Langel; J Narvaez; S Tanganelli; C Lluis; S Ferré; A Woods; R Franco; L F Agnati
Journal:  J Neural Transm (Vienna)       Date:  2006-10-27       Impact factor: 3.575

Review 6.  An update on adenosine A2A-dopamine D2 receptor interactions: implications for the function of G protein-coupled receptors.

Authors:  S Ferré; C Quiroz; A S Woods; R Cunha; P Popoli; F Ciruela; C Lluis; R Franco; K Azdad; S N Schiffmann
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

Review 7.  Moonlighting proteins and protein-protein interactions as neurotherapeutic targets in the G protein-coupled receptor field.

Authors:  Kjell Fuxe; Dasiel O Borroto-Escuela; Wilber Romero-Fernandez; Miklós Palkovits; Alexander O Tarakanov; Francisco Ciruela; Luigi F Agnati
Journal:  Neuropsychopharmacology       Date:  2013-09-06       Impact factor: 7.853

Review 8.  Purinergic receptors as potential therapeutic targets in Alzheimer's disease.

Authors:  Lucas T Woods; Deepa Ajit; Jean M Camden; Laurie Erb; Gary A Weisman
Journal:  Neuropharmacology       Date:  2015-10-28       Impact factor: 5.250

Review 9.  Purinergic system in psychiatric diseases.

Authors:  A Cheffer; A R G Castillo; J Corrêa-Velloso; M C B Gonçalves; Y Naaldijk; I C Nascimento; G Burnstock; H Ulrich
Journal:  Mol Psychiatry       Date:  2017-09-26       Impact factor: 15.992

Review 10.  Dopamine receptor homooligomers and heterooligomers in schizophrenia.

Authors:  Melissa L Perreault; Brian F O'Dowd; Susan R George
Journal:  CNS Neurosci Ther       Date:  2010-12-28       Impact factor: 5.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.